

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**A case of nonfatal intoxication associated with the recreational use of diphenidine**

**This is a pre print version of the following article:**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1657787> since 2018-01-16T17:38:35Z

*Published version:*

DOI:10.1111/1556-4029.13355

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)



## A case of non-fatal intoxication associated with the recreational use of diphenidine

Journal:	<i>Journal of Forensic Sciences</i>
Manuscript ID	JOFS-16-204
Manuscript Type:	Case Report
Date Submitted by the Author:	12-Apr-2016
Complete List of Authors:	Gerace, Enrico; Centro Regionale Antidoping "A. Bertinaria", Bovetto, Elena; ASL TO5, Ospedale Maggiore , Dipartimento di Anestesia e Rianimazione Di Corcia, Daniele; Centro Regionale Antidoping "A. Bertinaria" Vincenti, Marco; Centro Regionale Antidoping "A. Bertinaria"; Universita degli Studi di Torino, Dipartimento di Chimica Salomone, Alberto; Centro Regionale Antidoping "A. Bertinaria"
Keywords:	Forensic science, Diphenidine, Dissociative drugs, New psychoactive substances, Intoxication, Designer drugs

SCHOLARONE™  
Manuscripts

Review

1  
2  
3 **A case of non-fatal intoxication associated with the recreational use of**  
4  
5 **diphenidine**  
6  
7

8 Enrico Gerace<sup>1\*</sup>, Elena Bovetto<sup>2</sup>, Daniele Di Corcia<sup>1</sup>, Marco Vincenti<sup>1,3</sup> and Alberto Salomone<sup>1</sup>  
9

10 <sup>1</sup>*Centro Regionale Antidoping "A. Bertinaria", Regione Gonzole 10/1, 10043 Orbassano, Turin,*  
11  
12 *Italy*  
13

14 <sup>2</sup> *ASL TO5, Ospedale Maggiore - Dipartimento di Anestesia e Rianimazione, Via De Maria 1,*  
15  
16 *10023 Chieri, Turin, Italy*  
17

18 <sup>3</sup>*Dipartimento di Chimica, Università degli Studi di Torino, via P. Giuria 7, 10125 Turin, Italy*  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38

39 **\*Corresponding author:** Enrico Gerace, PhD  
40

41 Centro Regionale Antidoping "A. Bertinaria",  
42

43 Regione Gonzole, 10/1 – 10043 Orbassano (Turin) – Italy  
44

45 Tel: +3901190224249, Fax: +3901190224242, Mobile: +393393795125  
46  
47

48 E-mail address: [enrico.gerace@antidoping.piemonte.it](mailto:enrico.gerace@antidoping.piemonte.it)  
49  
50  
51

52 **Keywords:** Forensic science; Diphenidine; Dissociative drugs; New psychoactive substances,  
53 Intoxication; Designer drugs.  
54  
55  
56  
57  
58  
59  
60

**ABSTRACT**

Diphenidine is a dissociative drug commonly sold online as research chemical. Several psychotropic effects can appear during diphenidine intoxication including euphoria, shifts in perception of reality, hallucinations and transient anterograde amnesia.

In this study, we report a case of acute intoxication occurring after diphenidine intake.

A 30-year-old Caucasian male was hospitalized after he was found in a confused and agitated state, and unable to communicate. The physical examination displayed tachycardia, miotic pupils and increased body temperature and respiratory rate. GC/MS analysis revealed the presence of diphenidine in plasma and urine at concentrations of 308 and 631 ng/mL, respectively. Plasma analysis also revealed the presence of methylphenidate and diclazepam. The clinical progress of the patient was favourable and his symptoms were cured with a symptomatic treatment.

The combined circumstantial elements and toxicological results of the case reported revealed the occurrence of an acute intoxication ascribable to the recreational abuse of diphenidine.

1  
2  
3 Diphenidine (1-(1,2-diphenylethyl)piperidine) is a dissociative anaesthetic designer drug  
4  
5 structurally related to arylcyclohexylamines like phencyclidine (PCP), ketamine and methoxetamine  
6  
7 (MXE) (1). Diphenidine was first synthesized in 1924 and studied as a neuroprotective agent for the  
8  
9 treatment of brain injury following hypoxia (2). Diphenidine can act as N-methyl-D-aspartate  
10  
11 (NMDA) receptor antagonists, serotonin transporter inhibitors, dopamine agonists and opioid  
12  
13 agonist, producing dissociative effects similar to those induced by ketamine and MXE (1,3). For  
14  
15 this reason, diphenidine and its analogues are candidated to be used as a recreational drug, mainly  
16  
17 among users of new psychoactive substances. All these drugs are available from internet suppliers  
18  
19 and sold as research chemicals 'not for human consumption'(4). Diphenidine is generally sold as  
20  
21 white or slightly yellowish powder or fine crystals. The most common routes for recreational intake,  
22  
23 reported by drug users in web discussion forums, are nasal insufflation (snorting) and oral ingestion  
24  
25 (3). Due to the fact that this drug is not used for medical purposes, the information about its  
26  
27 pharmacology, side-effects, and toxicology are very limited. In the reports collected on web forums,  
28  
29 diphenidine use is associated with strong dissociative effects starting at oral doses of 110 mg and  
30  
31 higher doses inducing bizarre somatosensory phenomena and transient anterograde amnesia, lasting  
32  
33 for 3–6 h (1).

34  
35  
36  
37  
38 Recently, Helander et al. described a series of 17 cases of intoxication due to the consumption of  
39  
40 diphenidine and methoxphenidine (5). The commonly recorded clinical features were hypertension,  
41  
42 tachycardia, anxiety, and altered mental status including confusion, disorientation, dissociation,  
43  
44 and/or hallucinations. The same symptoms were reported by Hofer et al. in an intoxication case  
45  
46 associated to the use of methoxphenidine (6). A case of acute and lethal intoxication related to the  
47  
48 simultaneous consumption of the synthetic cannabinoids AB-CHMINACA, 5-fluoro-AMB and  
49  
50 diphenidine were also reported in literature (7). In another study, the post-mortem distribution of  
51  
52 these drugs in body fluids and solid tissues was studied and similar cases of acute or fatal  
53  
54 intoxication associated with the use of the methoxy-analog of diphenidine, namely 2-methoxy-  
55  
56 diphenidine, were recently reported (8). However, little is still known about the correlation between  
57  
58  
59  
60

1  
2  
3 the blood concentration of these compounds and their effects. In this paper, we report a case of  
4 acute toxicity after diphenidine intake, in association with other psychoactive substances. The  
5 presence of the drug was confirmed in plasma and urine by means of mass spectrometry-based  
6 chromatographic methods.  
7  
8  
9  
10

### 11 12 13 14 **Case Report** 15

16  
17  
18 A 30-year-old Caucasian man with previous history of drug addiction was found seated alongside  
19 his bed in a confused and agitated state, and unable to communicate. On the floor, a small plastic  
20 bag was found, containing few milligrams of a white powder labelled 'Diphenidine 1g'. The content  
21 of the plastic bag was analytically confirmed by gas chromatography-mass spectrometry. No  
22 current medication was declared to the rescue unit by the subject's relatives. The first physical  
23 examination revealed tachycardia (heart rate 160 bpm), and miotic nonreactive pupils. The  
24 preliminary medical examination also verified a state of agitation, disorientation and altered  
25 consciousness with a Glasgow Coma Scale (GCS) of 9. Midazolam (30 mg intravenously, divided  
26 in repeated injections at increasing dosages) was initially administered for sedation. No traces of  
27 vomit were found. On arrival at the emergency department, the patient was still agitated and  
28 uncontrollable, with major muscular rigidity. The physical examination displayed tachycardia (160  
29 bpm), tachypnea and miotic pupils. The external body temperature recorded was 38.0°C. Blood gas  
30 analysis revealed severe metabolic acidosis with blood pH 7.17 (reference 7.35–7.45), base excess  
31 (BE) of –14 mmol/L (reference from –2 to +2 mmol/L) and lactate concentration of 13 mEq/L  
32 (reference <4mEq/L). The patient was treated for sedation with midazolam (15 mg intravenously),  
33 diazepam (10 mg intravenously), chlorphenamine maleate (10 mg intravenously), haloperidol (2 mg  
34 intravenously) and sodium bicarbonate 5% m/v (250 mL intravenously). After 90 min, the patient  
35 regained consciousness but his speech was still drowsy and slowed. His pupils were still miotic but  
36 no amnesia phenomenon was reported. The ECG and the respiratory rate were normal, while the  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 body temperature was around 37.0 °C. The patient admitted to have taken the diphenidine powder  
4  
5 by nasal insufflations about five hours before the rescuer arrival at his home. Twelve hours after the  
6  
7 hospitalization, laboratory analysis revealed an increase of creatine kinase (CK: 87923 U/L;  
8  
9 reference < 190 U/L), alanine aminotransferase (ALT: 77 U/L; reference < 40 U/L), aspartate  
10  
11 aminotransferase (AST: 500 U/L; reference < 37 U/L), and lactate dehydrogenase (LDH: 4908 U/L;  
12  
13 reference 240–480 U/L) indicating rhabdomyolysis. After two hours, the blood pressure was  
14  
15 reverted to 115/70 mmHg, with an heart rate of 88 bpm and a body temperature back to 36.6 °C.  
16  
17 Twelve hours after arrival at the Emergency Department, the patient was relaxed and drowsy, but  
18  
19 easily aroused by verbal stimulation. His blood pressure was stable at 125/70 mmHg, with an heart  
20  
21 rate of 65 bpm. After 5 days of observation, the patient was discharged. CK, ALT, AST and LDH  
22  
23 trends recorded during the hospitalization period are shown in Figure 1. Blood and urine samples  
24  
25 were collected on admission and submitted to the laboratory for toxicological analyses. Moreover,  
26  
27 an hair lock sample was collected as additional matrix and tested for the presence of several new  
28  
29 psychoactive substances with stimulant, psychedelic, and dissociative properties.  
30  
31  
32  
33  
34  
35

### 36 **Toxicological analysis**

37  
38  
39  
40  
41 Immunochemical toxicology screening on urine was performed by Enzyme Multiplied  
42  
43 Immunoassay Technique (EMIT, Abbott Laboratories, IL, USA) and turned out positive for  
44  
45 benzodiazepines and cannabinoids, and negative for cocaine, amphetamine, opioids, barbiturates,  
46  
47 methadone, tricyclic antidepressants, 3,4-methylenedioxymethamphetamine and  
48  
49 methamphetamines. Screening analysis for unknown substances was performed in urine, plasma  
50  
51 (both extracted with TBME at alkaline conditions) and the powder found beside the patient at his  
52  
53 home by gas chromatography/mass spectrometry. Full scan spectra in the interval 40-650 amu were  
54  
55 acquired using a 5975 inert mass-selective detector (Agilent Technologies, Milan, Italy) operating  
56  
57 in the EI mode at 70 eV. The qualitative identification of the compounds was performed by  
58  
59  
60

1  
2  
3 comparing the full scan spectra obtained with those recorded in the updated spectra libraries  
4 (PMWTox2, SWGDRUG version 1.7, AAFS2012, CaymanSpectraLib). For the diphenidine  
5 confirmation analysis, a dedicated GC-MS procedure was developed. A 6890N gas chromatograph  
6 from Agilent Technologies (Milan, Italy) equipped with a J&W HP-5 capillary column, 17 m ×  
7 0.200 mm × 0.33 μm was used. Helium was employed as the carrier gas at a constant pressure of  
8 30.00 psi. The GC oven temperature was set at 90°C for 1 min and then raised to 180°C with a  
9 30°C/min heating rate. The oven temperature was maintained at 180 °C for 7 min and then raised to  
10 315 °C with a 15 °C/min heating rate. The total run time was 23 min. The GC injector and transfer  
11 line were maintained at 280°C.

12  
13  
14 The chromatograph was coupled to a 5975-inert MSD from Agilent Technologies (Milan, Italy)  
15 with EI at 70 eV. Quantitative determination of diphenidine was performed by monitoring the  
16 diagnostic ions at m/z 174 (target ion), 175 and 91 (qualifiers), whereas for the internal standard  
17 (ethaverine), the diagnostic ions at m/z 366, 280 and 394 were chosen.

18  
19  
20 Other confirmation analyses on blood, urine and hair were performed by means of updated liquid  
21 chromatography/tandem-mass spectrometry (LC/MS-MS) methods routinely employed in our  
22 laboratory (9,10,11,12).

## 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 **Results**

42  
43  
44  
45 Diphenidine was identified as the only component of the powder. The same compound was  
46 quantified in plasma and urine specimens at concentrations of 308 ng/mL and 631 ng/mL,  
47 respectively. Moreover, diphenidine was detected in hair sample at 4400 pg/mg concentration.  
48 Other findings included α-PVP (1040 pg/mg), MDPV (120 pg/mg), methoxetamine (27 pg/mg), 4-  
49 fluoroamphetamine (55 pg/mg) and methylone (traces). Several other drugs were quantitatively  
50 determined in plasma, some of which had been administered in hospital. These included  
51 benzodiazepines such as diazepam, nordiazepam, delorazepam (chlordesmethyldiazepam),  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 lormetazepam, lorazepam and midazolam, together with haloperidol and methylphenidate.  
4  
5 Moreover, the designer benzodiazepine diclazepam was also found in the patient's plasma sample at  
6  
7 a concentration of 3.5 ng/mL. All the findings in plasma and urine samples are summarized in Table  
8  
9  
10 1.

## 11 12 13 14 **Discussion**

15  
16 Dissociative drugs distort perceptions of sight and sound and produce feelings of detachment (or  
17  
18 dissociation) from the environment and self. Among the dissociative drugs, ketamine and  
19  
20 phencyclidine (PCP) are the drugs most commonly used for recreational purpose. In the last 5 years,  
21  
22 a new generation of synthetic dissociative drugs appeared on the market, including methoxethamine  
23  
24 (MXE), methoxphenidine, diphenidine and phencyclidine derivatives (e.g. 4-MeOPCP), which have  
25  
26 rapidly spreaded as a legal replacements for the banned ketamine and PCP (1). The introduction of  
27  
28 new psychoactive drugs on the market make it difficult to identify the substances responsible for  
29  
30 intoxication cases that turn up at the emergency departments. Once identified, very few data are  
31  
32 generally available in the literature about these substances, their metabolism, acute and chronic  
33  
34 toxicity, and clinical symptoms that they produce. Moreover, the consumers of new psychoactive  
35  
36 substances (NPS) frequently combine the intake different type of drugs resulting in unpredictable  
37  
38 serious interactions with related clinical signs difficult to interpret.

39  
40  
41  
42 In a study reporting 17 intoxication cases produced by consumption of diphenidine and  
43  
44 methoxphenidine, common adverse symptoms reported were hypertension (systolic blood pressure  
45  
46 > 140 mmHg), tachycardia (heart rate > 100 bpm), anxiety, agitation, nystagmus, dilated pupils and  
47  
48 muscle rigidity (5). Moreover, altered mental status was sometimes recorded, including modified  
49  
50 level of consciousness, hallucinations, confusion, disorientation and dissociation. In another case of  
51  
52 acute toxicity associated with the recreational use of methoxphenidine, symptoms such as  
53  
54 tachycardia (112 bpm), hypertension (220/125 mmHg), echolalia, confusion, agitation,  
55  
56 opisthotonus, nystagmus and amnesia were recognized in the intoxicated patient (6). Moreover, an  
57  
58  
59  
60

1  
2  
3 increase of blood creatine kinase (max 865 U/L), alanine aminostransferase (72 U/L) and gamma-  
4  
5 glutamyl transpeptidase (123 U/L) was also reported.  
6

7 In the present case, the patient showed symptoms such as agitation, disorientation and altered  
8  
9 consciousness state. Moreover, tachycardia, increased respiratory rate, miotic pupils and muscular  
10  
11 rigidity were reported and blood analysis revealed signs of metabolic acidosis and rabdomiolysis.  
12

13 All the symptoms observed were compatible with the effects induced by dissociative drugs like  
14  
15 MXE, ketamine, PCP and the new diphenidine and methoxphenidine drugs (5,6,13,14). The  
16  
17 concentration of diphenidine found in plasma (308 ng/mL) was comparable to those of diphenidine  
18  
19 and methoxphenidine in the 17 intoxication cases associated with the consumption of these drugs  
20  
21 (2-409 ng/mL; mean: 122 ng/mL; median: 93 ng/mL) (5). This concentration is also 4-80 fold lower  
22  
23 than those observed in three fatalities involving methoxphenidine (8). In the patient of the present  
24  
25 case, benzodiazepines were administered together with haloperidol for sedation and for the  
26  
27 treatment of tachycardia and hypertension. All the other detected substances (excluding  
28  
29 methylphenidate and diclazepam) had been used during the therapy in hospital. The simultaneous  
30  
31 detection in urine and plasma samples of delorazepam, lormetazepam and lorazepam is compatible  
32  
33 with a diclazepam intake, as was demonstrated in a controlled study on diclazepam metabolism  
34  
35 (15). In current literature there are very little data on diclazepam levels in biological fluids. The  
36  
37 blood concentration found in the presented case (3.5 ng/mL) is comparable to that registered 3  
38  
39 hours after an oral intake of a 1 mg tablet of diclazepam by a 43 years old male subject (weight 73  
40  
41 kg) in a study published by Moosmann et al. (15). Concerning methylphenidate, although the  
42  
43 recorded blood concentration (3 ng/mL) was below the therapeutic levels (5-60 ng/mL) (16), a  
44  
45 possible synergic stimulant effect in combination with diphenidine cannot be excluded. The  
46  
47 detection of diclazepam and methylphenidate in the patient's plasma sample suggests that these  
48  
49 drugs have most likely been consumed together with diphenidine or within a restricted period of  
50  
51 time, potentially influencing and reinforcing their effects. Designer benzodiazepines are often taken  
52  
53 as 'self medication' by users of stimulant and hallucinogenic drugs, leading to 'upper downer'  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 cycles' (17). Lastly, the presence of diphenidine, together with  $\alpha$ -PVP, MDPV, methoxetamine, 4-  
4 fluoroamphetamine and methylone, in the hair sample indicates that the subject had previously  
5 been exposed to these drugs in more than one occasion.  
6  
7

8  
9 In conclusion, diphenidine appears to have acute toxicity similar to that of other dissociative drugs  
10 like ketamine, phencyclidine and other new designer drugs, such as methoxetamine and  
11 methoxphenidine. Due to the increasing diffusion of these drugs, occasional cases of intoxication  
12 from diphenidine consumption are likely to occur, with consequent access to emergency rooms and  
13 subsequent hospitalization of the drug users. Despite the lack of data and case reports in the current  
14 literature, it is advisable that the whole symptoms are promptly recognized and an adequate  
15 treatment is implemented for patients whose intoxication cause cannot be immediately identified.  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- [1] Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs. *Drug Test Anal* 2014; 6:614-632.
- [2] Gray NM, Cheng BK. EP patent 0346791, Preparation of "1,2-diarylethylamines for treatment of neurotoxic injury". EU Patent No 0346791A1. 1989, assigned to G.D. Searle & Co.
- [3] Schifano F, Orsolini L, Papanti GD, Corkery GM. Novel psychoactive substances of interest for psychiatry. *World Psychiatry* 2015; 14:15-26.
- [4] Wallach J, Kavanagh PV, McLaughlin G, Morris N, Power JD, Elliot SP, Mercier MS, Lodge D, Morris H, Dempster NM, Brandt SD. Preparation and characterization of the 'research chemical' diphenidine, its pyrrolidine analogue, and their 2,2-diphenylethyl isomers. *Drug Test Anal* 2014; 7:358-367.
- [5] Helander A, Beck O, Bäckberg M. Intoxications by the dissociative new psychoactive substances diphenidine and methoxphenidine. *Clin Toxicol* 2015; 53:446-453.
- [6] Hofer EK, Degrandi C, Müller DM, Zürcher-Härdi U, Wahl S, Rauber-Lüthy C, Ceschi A. Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine. *Clin Toxicol* 2014; 52:1288-1291.
- [7] Hasegawa K, Wurita A, Minakata K, Gonmori K, Nozawa H, Yamagishi I, Watanabe K, Suzuki O. Postmortem distribution of AB-CHMINACA, 5-fluoro-AMB, and diphenidine in body fluids and solid tissues in a fatal poisoning case: usefulness of adipose tissue for detection of the drugs in unchanged forms. *Forensic Toxicol* 2015; 33:45-53.
- [8] Elliot SP, Brandt SD, Wallach J, Morris H, Kavanagh PV. First reported fatalities associated with the 'Research Chemical' 2-methoxydiphenidine. *J Anal Toxicol* 2015; 39:287-293.
- [9] Salomone A, Gerace E, Brizio P, Gennaro MC, Vincenti M. A fast liquid chromatography-tandem mass spectrometry method for determining benzodiazepines and analogues in urine. Validation and application to real cases of forensic interest. *J Pharm Biomed Anal* 2011; 56: 582-591.
- [10] Vincenti M, Cavanna D, Gerace E, Pirro V, Petrarulo M, Di Corcia D, Salomone A. Fast screening of 88 pharmaceutical drugs and metabolites in whole blood by ultrahigh-performance liquid chromatography-tandem mass spectrometry. *Anal Bioanal Chem* 2013; 405:863-879.
- [11] Gerace E, Salomone A, Di Corcia D, Mazzucco P, Vincenti M. Postmortem redistribution of triazolam, alprazolam, delorazepam (chlordesmethyldiazepam) and zolpidem in a suicide case. *Toxicol Anal Clin* 2015; 27:233-238.

- 1  
2  
3 [12] Salomone A, Gazzilli G, Di Corcia D, Gerace E, Vincenti M. Determination of cathinones and other stimulant,  
4 psychedelic, and dissociative designer drugs in real hair samples. *Anal Bioanal Chem* 2016; 408:2035-2042.  
5  
6 [13] Wood DM, Davies S, Puchnarewicz M, Johnston A, Dargan P I. Acute toxicity associated with the recreational  
7 use of the ketamine derivative methoxetamine. *Eur J Clin Pharmacol* 2012; 68:853-856.  
8  
9 [14] McCarron MM, Schulze BW, Thompson GA, Conder MC, Goetz WA. Acute phencyclidine intoxication:  
10 clinical patterns, complications and treatment. *Ann Emerg Med* 1981; 10:290-297.  
11  
12 [15] Moosmann B, Bisel P, Auwärter V. Characterization of the designer benzodiazepine diclazepam and  
13 preliminary data on its metabolism and pharmacokinetics. *Drug Test Anal* 2014; 6:757-63.  
14  
15 [16] The International Association of Forensic Toxicologists. TIAFT reference blood level list of therapeutic and  
16 toxic substances, 2004.  
17  
18 [17] Moosmann B, King LA, Auwärter V. Designer benzodiazepines: a new challenge. *World Psychiatry* 2015;  
19 14(2):248.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 1:** trend of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK) and lactate dehydrogenase (LDH) in patient's blood during the period of admission.

For Peer Review

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 1  
144x115mm (300 x 300 DPI)

**Table 1:** analytical findings in plasma and urine samples

Analytes	Plasma (ng/mL)	Urine (ng/mL)
Diphenidine	308	631
Diazepam	376	2.0
Nordiazepam	7.0	neg
Temazepam	3.6	neg
Diclazepam	3.5	neg
Lormetazepam	2.4	345
Delorazepam	45	71
Lorazepam	5.1	212
Midazolam	214	73
Haloperidol	4.0	n/p
Methylphenidate	3.0	<LOQ
THC metabolite*	neg	120

\*11-nor-9-carboxy-delta-9-tetrahydrocannabinol

n/p: analysis not performed